# An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

> **NCT00092183** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 866 (actual)

## Conditions studied

- Nausea
- Vomiting
- Breast Neoplasms

## Interventions

- **DRUG:** MK0869, aprepitant / Duration of Treatment: 3 days
- **DRUG:** Comparator: ondansetron / Duration of Treatment: 3 days

## Key facts

- **NCT ID:** NCT00092183
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10-10
- **Primary completion:** 2003-12-01
- **Final completion:** 2004-02-11
- **Target enrollment:** 866 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092183, "An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00092183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*